Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Comparison of 8 vs 15 Days Antibiotic Treatment for Early-Onset VAP
NCT01559753Phase 4Completed
- Sponsor
- CHU de Besançon
- Start
- Jan 1998
- Primary completion
- Sep 2002
- Modality
- Reversible Covalent Inhibitors
01
Overview
Phase 4, randomised, open-label trial of amoxicillin + clavulanate, ceftriaxone, cefotaxime, tobramycin, netilmicin and 1 more in ventilator-associated pneumonia (VAP) (2 arms), sponsored by CHU de Besançon. Primary endpoint: Cure of respiratory infection at 21 days. Started Jan 1998; status: completed.
02
Drugs
amoxicillin + clavulanateceftriaxonecefotaximetobramycinnetilmicin
03
Conditions
ventilator-associated pneumonia (VAP)
Beyond the preview
Go deeper on NCT01559753.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01559753.